Advances in Vaccine Development for Human Lymphatic Filariasis

Ramaswamy Kalyanasundaram; Vishal Khatri; Nikhil Chauhan

doi:10.1016/j.pt.2019.11.005

Advances in Vaccine Development for Human Lymphatic Filariasis

Trends Parasitol. 2020 Feb;36(2):195-205. doi: 10.1016/j.pt.2019.11.005. Epub 2019 Dec 19.

Authors

Ramaswamy Kalyanasundaram¹, Vishal Khatri², Nikhil Chauhan²

Affiliations

¹ Department of Biomedical Sciences, College of Medicine, University of Illinois, 1601 Parkview Avenue, Rockford, IL 61107, USA. Electronic address: ramswamy@uic.edu.
² Department of Biomedical Sciences, College of Medicine, University of Illinois, 1601 Parkview Avenue, Rockford, IL 61107, USA.

Abstract

According to the World Health Organization, over 880 million people are currently at risk of acquiring lymphatic filariasis (LF) in over 52 countries worldwide. Current approaches to control LF by 2020 are short of the anticipated goal. Several studies suggest the existence of protective immunity against LF in humans. Thus, it is possible to develop a prophylactic vaccine against LF in humans. Several potential vaccine candidates were identified and tested for their potential against LF. To date, preclinical studies suggest that it is possible to develop a prophylactic vaccine against LF. Much work needs to be done, but it is clear that a prophylactic vaccine, combined with targeted chemotherapy, is critically required for eliminating LF worldwide.

Keywords: MDA; control; lymphatic filariasis; vaccine.

Publication types

Research Support, N.I.H., Extramural
Review

MeSH terms

Antigens, Helminth / immunology*
Elephantiasis, Filarial / immunology
Elephantiasis, Filarial / prevention & control*
Humans
Vaccines*

Substances

Antigens, Helminth
Vaccines

Abstract

Publication types

MeSH terms

Substances

Grants and funding